跳转至内容
Merck
CN

SML2952

Sigma-Aldrich

Tasisulam

≥98% (HPLC)

登录查看公司和协议定价

别名:
LY 573636, LY-573636, LY573636, N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide, N-(5-Bromothiophen-2-ylsulfonyl)-2,4-dichlorobenzamide, N-[(5-Bromo-2-thienyl)sulfonyl]-2,4-dichlorobenzamide
经验公式(希尔记法):
C11H6BrCl2NO3S2
分子量:
415.11
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

InChI

1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)

InChI key

WWONFUQGBVOKOF-UHFFFAOYSA-N

生化/生理作用

Tasisulam (LY573636) is a SPLAM (SPLicing inhibitor sulfonAMide) that bridges RNA binding motif protein 39 (RBM39; CAPERα, HCC1) and DCAF15 for interaction, thereby promoting (CUL4-DDB1-DDA1-DCAF15) E3 ubiquitin ligase complex-mediated RBM39 ubiquitination and subsequent proteasomal degradation. Tasisulam exerts selective toxicity in parental HCT116 cancer cultures (IC50 = 6.5 μM), but not those harboring non-CUL4-DCAF15-associating RBM39 G268V mutant even at a high concentration of 50 μM.

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ting Han et al.
Science (New York, N.Y.), 356(6336) (2017-03-18)
Indisulam is an aryl sulfonamide drug with selective anticancer activity. Its mechanism of action and the basis for its selectivity have so far been unknown. Here we show that indisulam promotes the recruitment of RBM39 (RNA binding motif protein 39)
Everett J Perkins et al.
European journal of drug metabolism and pharmacokinetics, 43(3), 355-367 (2017-11-10)
Cytochrome P450 2C9 (CYP2C9) is involved in the biotransformation of many commonly used drugs, and significant drug interactions have been reported for CYP2C9 substrates. Previously published physiologically based pharmacokinetic (PBPK) models of tolbutamide are based on an assumption that its metabolic
Tyler B Faust et al.
Nature chemical biology, 16(1), 7-14 (2019-11-07)
The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. While the activity critically depends on the cullin RING ligase substrate receptor DCAF15, the molecular details remain elusive. Here we
Timothy Meier et al.
Molecular cancer therapeutics, 10(11), 2168-2178 (2011-09-10)
LY573636-sodium (tasisulam) is a small molecule antitumor agent with a novel mechanism of action currently being investigated in a variety of human cancers. In vitro, tasisulam induced apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell
Talin Haritunians et al.
Oncology reports, 20(5), 1237-1242 (2008-10-25)
LY573636-sodium is a promising anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo. Moreover, studies have shown that the compound is selectively toxic towards tumor cells over their normal

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门